Clay Siegall: Pioneer in the Business of Genetics

As a person approaching middle age, if there is one thing Clay Siegall realizes it is that he has much to learn. Although he has contributed much to the neighborhoods throughout Seattle, he lives by this adage: “In your 20’s, you are almost certain you know everything. In your 30’s, you begin to realize you don’t. And in your 40’s, you realize that there is still much for you to learn.”

Now, of course, you would think that a man like Clay Siegall would not have much time for side activities, but even he realizes that sometimes extra things can be the impetus to help people in other areas and get them to trust him and his country. That is why he keeps a powerfully interesting blog besides being the CEO of Seattle Genetics.

He particularly enjoys sharing new stories he encounters on NPR. There is also no question that Clay Siegall has established himself as an avid viewer of NPR simply because of the many reports that he enjoys sharing. First of all, there is an appealing story where he discusses the latest findings by the Mars Curiosity Rover that is current moving around on Mars. He notes that the Rover recently uncovered a great view of many of the mountains on Mars and has been sending back some amazing panoramic photo views of the nearest neighbor in our solar system.

Siegall also reveals his interest in engineering on another one of his blog posts. He marvels at the unique craftsmanship of the Pushkin Bridge, which overlooks the Moskva River in Moscow.

While Dr. Siegall realizes the importance of attention with the public, he also realizes the importance of hard work. As the founder of Seattle Genetics, he is responsible for spearheading the important research into new drugs and helping get them ready for the market. The process can take many, many years, but as a scientist Dr. Siegall has the leadership and patience to make it happen. He works extremely hard day in and day out, making sure that Seattle Genetics is able to obtain the needed licenses to bring a new drug to market. Hats off to Dr. Siegall!